SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI
|
|
|
-22.24%
in
50 days
BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that develops new indications for approved drug compounds by applying its proprietary drug delivery technology platform, BEMA (BioErodible MucoAdhesive) Film Technology, while seeking FDA approval through the 505(b)(2) pathway, which represents a lower risk / cost and quicker route to commercialization as compared to the process of developing new chemical entities or biological agents. BDSI focuses on the niche market of pain management and supportive cancer care. <> <> <font> <>http://www.mikehavrx.com...
|
FDA Calendar Updates: Still Waiting on BDSI
BDSI
|
|
|
-8.30%
in
93 days
(closed on 10/15/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 258 entries as of 7/14/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
20 Extreme Trades on Pending FDA Decisions
BDSI
|
|
|
-15.09%
in
23 days
(closed on 07/14/09)
<> Below are 20 extreme trades among companies with market caps under $500 million from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/21/09) which have pending FDA decisions for either new drug products or biological agents that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlig...
|
FDA Calendar Updates: BDSI is Worth the Wait, Zicam Warning
BDSI
|
|
|
+3.27%
in
5 days
(closed on 06/21/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates: BDSI, SVNT Deadlines Approach
BDSI
|
|
|
+0.63%
in
4 days
(closed on 06/16/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
From the Blogosphere
Cephalon Settles Barr Challenge – Analyst Blog
|
|
|
Earlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case with Barr Pharmaceuticals, which is now owned by Teva Pharmaceutical (TEVA). Barr was looking to market a generic version of Cephalon’s cancer pain management drug, Fentora.
As per the terms of the agreement, Barr has been granted a non-exclusive, royalty-free right to sell a generic version of Fentora in October 2018. However, if a generic version of Fentora enters the market prior to that date, Barr will be allowed to launch its generic version provided the other generic company does not...
|
A Regular Revenue Stream for BioDelivery Sciences Is Imminent
BioDelivery Sciences (BDSI) announced in a Thursday morning press release that the company's recently-FDA-approved treatment for breakthrough pain in cancer patients, Onsolis, is ready for a commercial launch.
The commercial launch of the product, according to the press release, will take place next week by the US subsidiary of Meda Pharmaceuticals. Meda, also according to the release, has already initiated a national sales campaign.
|
Taking Advantage of the BioDelivery Dip
<>Shares of BioDelivery Sciences (BDSI) ended the trading week last week at $4.24, a nearly 50% price cut from the stock's 52-week high of over $8. I know that many investors start feeling the panic set in when a stock that they thought was a winner, such as BDSI, starts to drop for no apparent reason. Many of those investors will then sell their shares as a result of that feeling of panic which, in my opinion, would be an example of selling on emotion - a trading practice of which I'm not a big fan.
I believe that BDSI is a stock that is being manipulated right now - I would call it 'the big...
|
Short Interest in BioDelivery Sciences Is Good News
A comment from a reader:
 I am considering your pick of BioDelivery Sciences (BDSI) and have done my own Due Diligence. What in your opinion explains the 12.39% current short interest? Also, what are the potential sales projections to market?
|
BioDelivery Sciences Can Now Be Considered a Long Term Growth Stock
Shares of BioDelivery Sciences (BDSI) jumped to over the five dollar mark once again as the company announced on Tuesday morning that the United States Patent Office has issued a US Patent Extending Exclusivity for the company's BEMA Delivery Technology until at least 2019.
While this news is encouraging both for the company and investors, BioDelivery will request a further extension of the patent into early 2020.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on BDSI |
Visit streetinsider.com
More Resources
|
About BioDelivery Sciences International Inc.
- Answers.com
